Surgery Branch recruiting patients to study new treatment for cancers with RAS mutations
RAS is a family of proteins that send signals to genes involved in cell growth. Mutations in RAS genes can cause overactive RAS signaling that results in increased cell growth and division, which can ultimately lead to cancer. Receptors on the surface of T cells are responsible for recognizing and responding to disease-producing agents such as mutated RAS. James Yang, M.D., of the Surgery Branch is leading a team of investigators who have generated a special T-cell receptor from mouse cells that can recognize the G12V mutation of RAS, which is found in many human cancer cells. This specially engineered T-cell receptor is inserted into human white blood cells by a retrovirus. These lymphocytes are then used to treat a subset of cancer patients who have a specific tissue type called HLA-A*1101, which is 15% of the U.S. population. The team wants to determine if this therapy is safe and can help shrink tumors that have the G12V RAS mutation.
For more information about this trial, please visit: https://ccr.cancer.gov/surgery-branch/james-c-yang. Adults 18 and older may contact Ellen Bodurian, RN, at 301-451-1927 to discuss eligibility.
To search all CCR clinicals trials, please visit: https://ccr.cancer.gov/clinical-trials.
To subscribe to the latest CCR clinical trials news, click here.Summary Posted: 07/2017